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Abstract
Modern anaesthetic techniques have resulted in the clinical presentation of
malignant hyperthermia to be more often indolent and/or insidious than truly
fulminant, as previously known in the anaesthetic community. We present four
recently referred cases to illustrate this point: one late-onset case, two patients
with slowly progressive hypercapnia as the sole sign and a fourth patient with
postoperative myalgias and elevated creatine kinase. We also discuss the
reasons for the shift in typical clinical presentation. The more insidious character
of malignant hyperthermia is most likely due to the lower triggering potency of
modern volatile anaesthetics, the mitigating effects of several intravenous drugs
(neuromuscular blocking agents, alpha 2 adrenergic receptor agonists, beta-
adrenergic blockade) or techniques (neuraxial anaesthesia) and the routine use
of end-tidal CO2 monitoring leading to the early withdrawal of triggering drugs.
Awareness among anaesthetists of this change in pr...
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The changing face of malignant hyperthermia: less fulminant, 
more insidious
L. Heytens*, P. Forget†, J. L. Scholtès‡, F. Veyckemans§
Summary
Modern anaesthetic techniques have resulted in the clinical presentation of malignant hyperthermia to be more often 
indolent and/or insidious than truly fulminant, as previously known in the anaesthetic community. We present four recently 
referred cases to illustrate this point: one late-onset case, two patients with slowly progressive hypercapnia as the sole sign 
and a fourth patient with postoperative myalgias and elevated creatine kinase. We also discuss the reasons for the shift in 
typical clinical presentation. The more insidious character of malignant hyperthermia is most likely due to the lower triggering 
potency of modern volatile anaesthetics, the mitigating effects of several intravenous drugs (neuromuscular blocking agents, 
alpha 2-adrenergic receptor agonists, beta-adrenergic blockade) or techniques (neuraxial anaesthesia) and the routine use of 
end-tidal CO
2
 monitoring leading to the early withdrawal of triggering drugs. Awareness among anaesthetists of this change in 
presentation is important since the clinical diagnosis is often more doubtful and, if corroborative evidence is not sought, the 
diagnosis may be delayed or missed altogether.
Key Words: anaesthetics volatile-halogenated hydrocarbons, complications, malignant hyperthermia, genetic fac-
tors, hyperthermia, phenotype
With the aim to provide a comprehensive ‘clinical case 
definition’, the ‘malignant hyperthermia (MH) clinical grad-
ing scale’ lists six indicators of an MH crisis: rigidity, muscle 
breakdown, respiratory acidosis, temperature increase, car-
diac involvement and “other indicators of metabolic derange-
ment not part of a single process”1. In the majority of cases 
during the era of halothane/succinylcholine use, a combi-
nation of most of these signs was reported, resulting in a 
qualitative likelihood of MH rank 5, ‘very likely’, or 6, ‘almost 
certain’. Hence, and in view of its then considerable morbid-
ity and mortality, MH became known as a fulminant event. 
However, changes in the practice of anaesthesia over the last 
few decades have resulted in more insidious MH patterns, 
making the immediate clinical diagnosis more difficult to 
establish. We present four recently referred cases to illustrate 
this point and discuss the likely reasons for this shift in clinical 
presentation.
Written informed consent was obtained from all patients 
for the case descriptions. With the aim to present these 
cases in a uniform way, we included personal and family 
anaesthetic history, positive clinical and biochemical find-
ings, in vitro contracture test (IVCT) results, histological and 
molecular genetic findings and pertinent negative findings. 
Details on the breathing circuit used are lacking but, since all 
crises occurred in adults, we assume these to be rebreath-
ing double-limb circuits with CO
2
 absorption, fresh-gas flow 
unknown and minute ventilation as stated. The diagnosis of 
MH susceptibility was confirmed by IVCT according to the 
protocol of the European Malignant Hyperthermia Group. 
This test is considered positive if a contracture of at least 2 
mN is obtained at a caffeine concentration of 2 mM or less 
and/or halothane concentration of 2 Vol% or less. The sen-
sitivity and specificity of this test have been reported to be 
99% and 94% respectively2.
Case 1
Male, 47 years old, 91 kg
First anaesthetic, scheduled for varicectomy. Personal his-
tory: strabismus. Negative anaesthetic family history. 
Induction of anaesthesia: propofol 200 mg, sufentanil 10 
mcg, cisatracurium 12 mg. Maintenance: 2 Vol% sevoflurane 
in O
2
/N20 mixture. No temperature monitoring, no warming 
device. Duration of anaesthesia: 150 minutes. During the first 
hour, end-tidal CO
2
 remained between 33 and 38 mmHg but 
rose steadily thereafter, reaching 50 mmHg after 1.5 hours. 
Despite increasing ventilation to 14 l/minute, end-tidal CO
2
 
reached 103 mmHg after 2.5 hours of sevoflurane administra-
tion. Arterial blood gases were: pH 7.1, pCO
2
 105.9 mmHg, 
pO
2
 91 mmHg, bicarbonate 32.3 mmol/l. Blood pressure 
decreased from 110/65 after induction to 80/45 mmHg at 
the end of anaesthesia; heart rate increased from 60 to 85 
bpm. Rectal temperature was 38°C. No rigidity was noted. 
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Dantrolene 100 mg was administered 15 minutes after stop-
ping sevoflurane, resulting in the normalisation of end-tidal 
CO
2
 over one hour. The serum creatine kinase (CK) level one 
hour postoperatively was 390 U/l (normal range 55 to 190 
U/l) and peaked at 16,650 U/l after 12 hours. Potassium 
reached 7 mmol/l. Acute renal failure did not occur. The MH 
clinical grading scale score was 45—rank 5, ‘very likely’. 
Muscle biopsy performed three months later revealed nor-
mal histology and an IVCT indicative of MH susceptibility (30 
mN contracture at 2 mM caffeine, 23 mN contracture at 2 
Vol% halothane). A full c-DNA 106 exon ryanodine receptor 
1 (RYR1) Sanger sequencing (gene coding for the ryanodine 
receptor) did not reveal any variants.
Case 2
Male, 16 years old, 50 kg 
Emergency surgery for a forearm fracture. Personal history: 
previous general anaesthesia for tonsillectomy without unto-
ward effects. As a well-conditioned athlete he was known to 
have a sinus bradycardia. Negative anaesthetic family history. 
Rapid-sequence induction: propofol 150 mg and suc-
cinylcholine 50 mg. Impression of insufficient relaxation of 
the mandible but endotracheal intubation was successfully 
achieved at the first attempt and subsequent mechanical 
ventilation was without any problem. Maintenance of anaes-
thesia: 3 Vol% sevoflurane in O
2
/air mixture supplemented 
with sufentanil IV; no further muscle relaxant was given. No 
temperature monitoring was used with no warming device. 
The duration of exposure to sevoflurane was 30 minutes. 
End-tidal CO
2
 monitoring revealed an increase to 55 mmHg 
over 30 minutes despite progressive augmentation of minute 
ventilation to 9.6 l/minute (rate 16 per minute, tidal volume 
600 ml). Auricular temperature was 35.1°C. The patient was 
normotensive and heart rate increased from 40 to 80 bpm.  
In view of the high end-tidal CO
2
 at a minute ventilation of 
9.6 l/min and suspicion of MH, anaesthesia was switched 
to intravenous propofol. Arterial blood gas analysis showed 
a pH of 7.31, pCO
2
 of 51 mmHg and a normal bicarbonate. 
Dantrolene was not administered. Postoperative serum CK 
level was not determined. MH clinical grading scale score 
was 15 (but possibly underestimated as serum CK level was 
unknown)—rank 3, ‘somewhat less than likely’. Histology was 
normal. The IVCT showed a contracture of 14 mN at 2 mM 
caffeine and 22 mN at 2 Vol% halothane. Baseline CK level 
three months after the event was normal. DNA analysis was 
not performed.
Case 3
Male, 66 years old, 95 kg 
Urgent laparoscopic appendicectomy for retrocaecal appen-
dicitis. Personal history: two uneventful previous general 
anaesthetics. Negative anaesthetic family history. In view of 
previous postoperative nausea and vomiting, rapid-sequence 
induction and propofol target-controlled infusion were 
planned. 
Induction of anaesthesia: midazolam 2 mg, propofol 300 
mg and succinylcholine 100 mg, followed by a continuous 
infusion of propofol supplemented with sufentanil, rocuro-
nium 50 mg and clonidine 300 mcg. No temperature moni-
toring was used and no warming device. During the course 
of anaesthesia no untoward events were noted, there were 
no signs of hypermetabolism and end-tidal CO
2
 remained 
between 35 and 40 mmHg during the 150-minute proce-
dure. The CK level, measured because of severe myalgias on 
the first day after surgery, was 20,005 U/l. Renal function 
remained within normal limits. MH clinical grading scale 
score was 30—MH rank 4, ‘somewhat greater than likely’. 
Four months later, his IVCT showed contracture of 4 mN at 
2 mM caffeine and 7 mN at 2 Vol% halothane. Histology was 
normal. DNA analysis was not performed.
Case 4
Male, 18 years old, 74 kg 
General anaesthesia for emergency osteosynthesis of 
a traumatic femoral fracture. Negative personal history. 
Negative anaesthetic family history. 
Induction of anaesthesia: femoral nerve block with ropi-
vacaine, followed by induction of general anaesthesia with 
propofol 200 mg, sufentanil 25 mcg, atracurium 40 mg. 
Maintenance of anaesthesia: 2 Vol% sevoflurane in O
2
/air 
mixture supplemented with sufentanil IV. No temperature 
monitoring, nor forced air warming. Duration of exposure to 
sevoflurane: 80 minutes. After 60 minutes of anaesthesia, 
end-tidal CO
2
 increased from 42 to 60 mmHg over 10 min-
utes. Minute ventilation in the meantime had been increased 
to 14 l/min (rate 22/minute, tidal volume 650 ml). Rectal 
temperature 36.8°C. The patient remained normotensive but 
heart rate increased from 70 to 100 bpm. Rigidity was not 
noted. An MH crisis was suspected on the basis of the inap-
propriate hypercapnia. Sevoflurane was stopped and anaes-
thesia was converted to intravenous propofol. The arterial 
blood gas analysis showed a pH of 7.32, pCO
2
 of 49 mmHg, 
pO
2
 of 283 mmHg and bicarbonate 25 meq/l. Dantrolene was 
not administered. Postoperative serum CK level was 1200 U/l 
and the potassium was 4.8 mmol/l. MH clinical grading scale 
score: -15—rank 3, ‘somewhat less than likely’. The IVCT one 
year later showed a contracture of 18 mN at 2 mM caffeine 
and 40 mN at 2 Vol% halothane. Light microscopy was nor-
mal. DNA analysis was not performed.
Discussion
MH is a pharmacogenetic disorder of skeletal muscle, 
transmitted as an autosomal dominant trait and manifests as 
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hypermetabolism during anaesthesia when susceptible indi-
viduals are exposed to volatile anaesthetics and/or succinyl-
choline. The clinical presentation reflects disturbed calcium 
homeostasis as a result of defects in the genes coding for 
the proteins involved in excitation-contraction coupling—the 
dihydropyridine-ryanodine receptor complex—which serves 
as the main calcium-release channel in striated muscle. The 
ensuing sarcolemmal calcium overload induces sudden, 
potentially lethal rhabdomyolysis. 
MH has most often been described as a clinically fulmi-
nant phenomenon, e.g. it is assumed that, upon exposure 
to triggering agents, MH-susceptible patients will typically 
present with a combination of rapidly evolving hypercapnia, 
haemodynamic instability, rigidity, hyperthermia and signs of 
rhabdomyolysis. Over the last decade however, the number 
of cases referred with only subtle clinical signs has increased. 
In view of the small numbers reported to our centre covering 
a population of only 11 million inhabitants, a true statisti-
cal analysis from our data is not possible. But as there is a 
paucity of literature on this topic, we present a series of 
four cases, out of a total of six investigated probands over 
18 months, with an insidious clinical pattern. During the 
same period, only one case was fulminant (MH clinical grad-
ing scale score 60—rank 6, ‘almost certain’); one clinically 
suspicious but insufficiently documented episode of MH was 
negated by IVCT.
The large spectrum of manifestations from subclinical to 
fulminant has always been reported3 but even a recent retro-
spective analysis of the characteristics of the index of adverse 
anaesthetics does not report this shift in clinical presenta-
tion4. However, studies of this magnitude are hampered in 
their data interpretation by the lack of a uniform reporting 
system, limited data availability and variability in diagnostic 
and management protocols. Therefore, in this study the 
44.2% of patients with a ‘less than likely’ or ‘unlikely’ clinical 
grading scale score are attributed to limitations in data collec-
tion rather than incomplete phenotypic presentation. On the 
other hand, one recent article by Schuster et al does address 
the difficulty in diagnosing abortive courses5.
Three of the four cases presented had a rank 3 or 4 on the 
MH grading scale, i.e. a qualitative likelihood of ‘somewhat 
less than likely’ to ‘somewhat greater than likely’. The first 
case had a likelihood of ‘very likely’ but a very slow onset pat-
tern. Subsequent IVCTs in all cases were indicative of MH sus-
ceptibility. Identifying a known MH causative mutation would 
have corroborated the in vitro diagnosis of MH in these 
patients, but as our health authorities only recently started to 
support Sanger sequencing in RYR1-myopathies, these results 
are not available yet (apart from Family 1). On the other 
hand, at least one more family member has been diagnosed 
with MH susceptibility by IVCT, indirectly substantiating the 
diagnosis in the probands.
Case 1 presented with both clinical and biochemical signs 
of perioperative rhabdomyolysis, which was, in retrospect, 
sufficiently indicative of MH susceptibility. Because of the 
slow onset of the signs, a presumptive diagnosis of MH was 
only considered after two hours of anaesthesia and for some 
time even felt to be an argument against MH by the attend-
ing anaesthetist. This pattern is more common than generally 
assumed, as evidenced by several similar reports over the last 
few years6–11. Regarding the more ‘indolent character’ of MH, 
a recent paper provides, for the first time, statistical evidence 
that the MH median onset time was significantly shorter for 
the cases that occurred before 1998, compared to the cases 
that occurred later12.
The absence of RYR1 mutations upon sequencing is unfor-
tunate as it excludes genetic diagnosis in this family. It is 
certainly not an argument against MH susceptibility, as it is 
well known that an RYR1 mutation is found in only 70% of 
patients with a positive IVCT13. CACNA1S cDNA sequencing is 
now being considered as two mutations in the gene CACNA1S 
on chrom1 (encoding the main subunit of the dihydropyridine 
receptor) are consistent with presumed pathogenicity in cur-
rent databases. The assessment of the pathogenicity of most 
of these variants, however, remains challenging14.
Cases 2 and 4 presented with ‘inappropriate hypercapnia’ 
as the sole disturbing finding. The anaesthetist was alerted 
by the progressive hypercapnia, which could not be cor-
rected by increasing minute ventilation to more than twice 
the minute volume expected to be sufficient for maintaining 
normocapnia under anaesthesia. Also, in these two cases the 
abatement of the symptoms without having administered 
dantrolene created doubt about the diagnosis. Case 3 was 
highly atypical: biochemical evidence of rhabdomyolysis was 
detected because the patient reported major myalgias the 
day after the administration of succinylcholine as a unique 
MH-triggering agent. 
The large variability in clinical presentation of MH is partly 
due to genetic, and partly due to anaesthesia-related, factors. 
Regarding differences in genotype, about 400 different RYR1 
mis-sense mutations have been reported to be potentially 
linked to MH susceptibility to date15, but only a small minority 
have been convincingly shown to be ‘causative of MH’ (see 
www.emhg.org). Apparently, some of these mutations have 
more profound functional consequences than others. This 
was demonstrated by Carpenter et al in 2009, who showed 
that different RYR1-variants are consistently associated with 
significant differences in IVCT response and serum CK level. 
They concluded that different mutations confer a differential 
calcium-conductance to the calcium channel13. Besides this, 
several anaesthesia-related factors are important. The par-
ticular inhalational anaesthetic used has an influence on the 
clinical course. Every inhalational agent, except nitrous oxide 
and xenon, has been implicated as a trigger, but the rela-
tive potency of the inhalational agents in this respect varies 
considerably. This has been shown by in vitro effects during 
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contracture testing16,17, by in vivo comparison in susceptible 
swine18 and by studying the time interval between induc-
tion of anaesthesia and the development of signs of MH in 
humans19. In the latter study, a statistically significant faster 
onset of the MH reaction was found with halothane (median 
20 minutes, range 5 to 45 minutes) versus enflurane (median 
55 minutes, range 20 to 480 minutes) versus sevoflurane 
(median 60 minutes, range 10 to 210 minutes). Data analysis 
from the North American Malignant Hyperthermia Registry 
showed a faster MH onset after halothane exposure than iso-
flurane, but not when compared to sevoflurane12. Since halo-
thane is only rarely used in human anaesthesia in Western 
countries, nowadays a slower onset pattern should be antici-
pated with the currently used volatile agents.
The extent to which MH develops is said to be time-weight-
ed and therefore short procedures, or withdrawal of volatile 
agents early in the reaction, result in too short an exposure 
to fully develop the syndrome. Symptoms may abate when 
exposure to the triggering agents ends, even when dant-
rolene is not administered. In this sense it can be hypoth-
esised that the widespread use of end-tidal CO
2
 monitoring 
since the 1990s has played an important role in the more 
timely diagnosis of MH, the subsequent early withdrawal of 
triggering drugs and, therefore, its less frequent full-blown 
presentation.
There is also evidence that the triggering is dose-depend-
ent. This can be deduced from the incremental contracture 
response of MH muscle seen after in vitro exposure to 
increasing concentrations of halothane. This is felt to be a 
contributing factor to MH being more prevalent and more 
fulminant in children who are exposed to higher concentra-
tions during inhalation induction, whereas adults are only 
exposed to the lower maintenance concentrations following 
an intravenous induction. 
Intravenous anaesthetic agents may either enhance or 
protect against the development of MH. Succinylcholine 
enhances the clinical response as the combination of suc-
cinylcholine with a volatile agent triggers an earlier reaction 
compared with a volatile agent alone, and survival rates 
appear to be lower20. Other intravenous anaesthetics oppose 
the triggering. Experiments in susceptible pigs have shown 
that thiopentone delays the onset. This has not been shown 
with propofol21. Likewise, non-depolarising neuromuscular 
blocking agents such as pancuronium have been shown to 
consistently delay its onset in MH-susceptible pigs22. Young et 
al reported that the administration of non-depolarising neu-
romuscular blocking drugs was associated with a significantly 
increased onset time and lower postoperative CK concentra-
tion in human MH23. Barbier et al described a slow-onset case 
of MH under sevoflurane anaesthesia combined with a mid-
thoracic epidural anaesthesia. Part of the explanation may be 
the sympatholytic effect of the epidural blockade7.
Clonidine, an alpha-2 agonist with central sympatholytic 
action, may blunt adrenergic reactivity and thereby the 
expected tachycardia and hypertension. The newer dexme-
detomidine attenuates sympathetically mediated responses 
to perioperative and thermal stress24. Likewise, although 
beta-adrenergic blockade does not completely prevent halo-
thane-induced MH in the porcine model, the signs are clearly 
delayed25.
Several cases have recently been published during which 
the diagnosis of MH was complicated in laparoscopic surgery 
because the increase in end-tidal CO
2
 and mild tachycardia 
induced by the CO
2
 in the pneumoperitoneum confounded 
their clinical interpretation8,9,26. However, the extra amount of 
CO
2
 absorbed through the peritoneum is modest compared 
to the overall CO
2
 production in the body. Measurements of 
the systemic absorption of CO
2
 with a metabolic monitor indi-
cate an increase in carbon dioxide production of 15% for peri-
toneal laparoscopy, and 40% to 60% in patients undergoing 
retroperitoneoscopy, and end-tidal CO
2
 could easily be main-
tained within normal limits by adjustment of minute ventila-
tion27. Therefore, the increase in minute volume needed to 
correct the hypercapnia is rarely >50%. In case 4, however, 
even doubling minute volume could hardly correct the hyper-
capnia and it is exactly this inappropriateness that points at 
hypermetabolism and a possible MH crisis. Therefore, we 
entirely agree with the dictum by Brown that “the most use-
ful clinical sign of MH is an end-tidal CO
2
 that continues to 
rise despite increasing ventilation”28. 
Although asymptomatic increased CK levels have, for years, 
been considered not to be a reliable predictor of MH suscep-
Table 1 
Factors potentially associated with a delayed onset of malignant hyperther-
mia or complicating its diagnosis
Delayed onset Missed/
complicated 
diagnosis
Reference
Inhalational anaesthesia
Short exposure X 19
Moderate or low 
concentrations
X X 19
Agent: sevoflurane and 
desflurane
X X 7,10,11,12
Other drugs/techniques
Thiopentone X
Non-depolarising 
neuromuscular blocking 
agents
X 9,22,23
Dexmedetomidine X 24
Beta-adrenergic 
antagonists
X 25
Epidural anaesthesia X 7
Laparoscopy X 6,8,9,26
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tibility, leading to the abandonment of the serum CK level 
as a screening test for MH29, in our opinion a watchful eye 
is still advised. Indeed, RYR1 mutations such as c.1021G>C 
(Gly341Arg) and c.487C>T (Arg163Cys) can be a specific 
cause of chronically elevated CK activity in patients with 
strictly normal histological findings30,31. Postoperative rhabdo-
myolysis, certainly if CK is more than 10,000 U/l without, and 
more than 20,000 U/l with, the use of succinylcholine, is very 
suspect and either points at an underlying myopathy or MH 
susceptibility. The exception may be morbidly obese patients 
who undergo prolonged procedures leading to a crush and/or 
compartment syndrome32.
The interactions of drugs and techniques with the presenta-
tion and/or the diagnosis of MH are summarised in Table 1.
Conclusion
Although MH can still present as a fulminant event in the 
true sense of the word, anaesthetists should be aware of the 
increasing proportion of insidious presentations. Whereas 
fulminant MH is characterised by a combination of rapidly 
evolving signs of hypermetabolism (hypercapnia, tachycardia, 
hypertension, hyperthermia), muscular symptoms (masseter 
spasm, rigidity) and rhabdomyolysis, more and more attenu-
ated presentations occur. We therefore recommend that in 
our current practice sufficient attention be paid to the follow-
ing signs or measures, even when occurring as a sole abnor-
mality:
• foremost: persistent, unexplained and difficult-to-correct 
hypercapnia,
• rapidly increasing and/or inappropriately elevated body 
temperature,  
• masseter spasm following the administration of succinyl-
choline and
• clinical or biochemical evidence of rhabdomyolysis: 
increased postoperative CK level, voiding of cola-coloured 
urine (myoglobinuria), with or without hyperkalaemia.
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